Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Key Highlights
- ➤STARLIGHT-1 activates Intermountain Health LDS Hospital as its fifth clinical site
- ➤EB103 expansion phase evaluates safety and efficacy at the recommended Phase II dose
- ➤New site is expected to begin screening and enrolling after initiation activities
- ➤Expansion data is expected to inform EB103’s pivotal trial strategy
Expert Statements
Cheng Liu, Chief Executive Officer of Estrella Immunopharma
“Intermountain Health LDS Hospital’s long-standing work in cellular therapy makes it a strong addition to STARLIGHT-1”
Cheng Liu, Chief Executive Officer of Estrella Immunopharma
“Each new site moves the dose-expansion phase forward and brings us closer to defining the path to a future pivotal study for EB103 in patients with R/R B-cell NHL.”
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS(®) T-cell therapies to treat cancers and autoimmune diseases, today announced the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a CD19-Redirected ARTEMIS(®) T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, Intermountain Health LDS Hospital, in Salt Lake City, Utah, is expected to begin screening and enrolling patients following completion of site initiation activities.
Get started
Create a free account to read the full story.